December 12, 2020
Article
Children with sickle cell disease have the opportunity to learn about STEM concepts in the context of their own condition.
December 09, 2020
Video
A continued conversation on the intricate, patient-centric benefits of care with the subcutaneous agent.
Podcast
The UCSF hematologist discusses the growing portfolio for the sickle cell therapy after ASH 2020.
December 08, 2020
New ASH data demonstrates that RUDAS and MoCA scores are associated with highest level of education.
Luspatercept added to best supportive care reduced transfusion burden while TranQol and SF-36 HRQoL scores were maintained through Week 48.
A Phase I study reports on the safety and potential efficacy of lintuzumab Ac225 plus CLAG-M for relapsed/refractory acute myeloid leukemia.
The historic phase 3 HOPE-B trial shows all but 1 treated patient discontinued prophylaxis after a single dose of etranacogene deaparvovec.
The second process of ARU-1801 in a new patient resulted in up to 4 times greater engraftment of transduced hematopoietic stem cells and progenitors at 6 months.
An interview with a Janssen expert on the growing portfolio and newest data for daratumumab.
December 07, 2020
The sickle cell disease subtype is associated with increased risk among patients as young as 2 years old.
